A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according ...
May 20, 2021
0
19
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20. The standard treatment ...
May 4, 2021
0
34
Children and young adults with compromised immune systems, such as those undergoing cancer treatment, may experience a prolonged period of infection with SARS-CoV-2, the virus that causes COVID-19, and the extended duration ...
Apr 28, 2021
0
5
When researchers from Penn Medicine found that many patients with B-cell acute lymphoblastic leukemia (ALL) treated with the investigational chimeric antigen receptor (CAR) T cell therapy targeting the CD22 antigen didn't ...
Apr 22, 2021
0
72
Steroids are essential for treating children with acute lymphoblastic leukemia, a type of cancer of the blood and bone marrow, but they can cause severe side effects such as psychological reactions and sleep problems. An ...
Apr 7, 2021
0
4
In some cancers, including leukemia in children and adolescents, obesity can negatively affect survival outcomes. Obese young people with leukemia are 50% more likely to relapse after treatment than their lean counterparts.
Apr 1, 2021
0
0
Children and young adults who receive CAR T-cell therapy for the most common childhood cancer, acute lymphoblastic leukemia, suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired ...
Apr 1, 2021
0
6
UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the ...
Mar 4, 2021
0
6
(HealthDay)—Hispanic/Latino (H/L) children with B-cell acute lymphoblastic leukemia (B-ALL) have an increased incidence of IKZF1 deletion and IGH-CRLF2 translocation, according to a letter to the editor published online ...
Feb 19, 2021
0
4
In a new study led by Yale Cancer Center, researchers have discovered a novel metabolic gatekeeper mechanism for leukemia. This mechanism depends on a molecule called PON2, which could lead to a new treatment for the disease. ...
Feb 1, 2021
0
64
